ProMIS Neurosciences (NASDAQ:PMN) Trading Down 1.7%

ProMIS Neurosciences, Inc. (NASDAQ:PMN)’s stock price traded down 1.7% during trading on Wednesday . The company traded as low as $1.61 and last traded at $1.68. 2,267 shares traded hands during trading, a decline of 92% from the average session volume of 29,052 shares. The stock had previously closed at $1.71.

ProMIS Neurosciences Price Performance

The stock has a 50-day moving average of $1.90 and a 200-day moving average of $1.81. The firm has a market cap of $30.59 million, a price-to-earnings ratio of -2.18 and a beta of 0.67.

ProMIS Neurosciences (NASDAQ:PMN) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.19) earnings per share for the quarter. On average, equities analysts expect that ProMIS Neurosciences, Inc. will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On ProMIS Neurosciences

A hedge fund recently bought a new stake in ProMIS Neurosciences stock. Affinity Asset Advisors LLC bought a new stake in ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 265,958 shares of the company’s stock, valued at approximately $527,000. Affinity Asset Advisors LLC owned about 3.10% of ProMIS Neurosciences at the end of the most recent quarter. 50.13% of the stock is currently owned by institutional investors.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.